Skip to main content
. 2019 Nov 14;43(2):358–365. doi: 10.2337/dc19-1483

Table 1.

Baseline characteristics of 3,257 post-MI patients from the Alpha Omega Cohort by quintiles of dietary and plasma LA

Quintiles of dietary LA (% energy) Quintiles of plasma LA (%)
Q1 (n = 651) Q3 (n = 651) Q5 (n = 651) Q1 (n = 652) Q3 (n = 651) Q5 (n = 651)
Median (range) 3.5 (1.2–4.1) 5.6 (5.1–6.2) 8.8 (7.6–13.9) 43.9 (28.5–46.1) 50.1 (48.9–51.4) 56.3 (54.3–67.6)
Age, years 69.4 ± 5.7 68.8 ± 5.5 68.6 ± 5.4 68.2 ± 5.7 68.7 ± 5.4 69.8 ± 5.5
Men 471 (72.4) 536 (82.3) 569 (87.4) 504 (77.3) 511 (78.5) 553 (85.0)
BMI, kg/m2 27.6 ± 3.7 27.4 ± 3.5 27.1 ± 3.2 27.6 ± 3.8 27.4 ± 3.2 26.7 ± 3.3
Time since MI, years 3.6 (1.5–6.3) 3.6 (1.7–6.1) 3.1 (1.4–6.3) 3.1 (1.4–5.9) 3.4 (1.5–6.2) 4.0 (1.8–6.6)
Smoking
 Never 136 (20.9) 102 (15.7) 86 (13.2) 92 (14.1) 109 (16.7) 112 (17.2)
 Former 414 (63.6) 452 (69.4) 432 (66.4) 417 (64.0) 440 (67.6) 435 (66.9)
 Current 101 (15.5) 97 (14.9) 133 (20.4) 143 (21.9) 102 (15.7) 103 (15.8)
Physical activity*
 Low 260 (40.2) 256 (39.4) 259 (40.0) 257 (39.5) 263 (40.4) 269 (41.3)
 Middle 228 (35.3) 247 (38.0) 262 (40.5) 266 (40.9) 250 (38.4) 243 (37.3)
 High 158 (24.5) 147 (22.6) 126 (19.5) 127 (19.5) 138 (21.2) 139 (21.4)
Highest level of education
 Primary 124 (19.2) 133 (20.5) 128 (19.8) 120 (18.5) 125 (19.2) 137 (21.1)
 Lower secondary 233 (36.0) 228 (35.1) 268 (41.4) 223 (34.4) 249 (38.2) 229 (35.2)
 Higher secondary or lower tertiary 209 (32.3) 203 (31.2) 189 (29.2) 208 (32.0) 202 (31.0) 203 (31.2)
 Higher tertiary 81 (12.5) 86 (13.2) 62 (9.6) 98 (15.1) 75 (11.5) 81 (12.5)
Alcohol intake*
 No 32 (4.9) 18 (2.8) 35 (5.4) 27 (4.1) 17 (2.6) 36 (5.5)
 Low 337 (51.8) 344 (52.8) 306 (47.0) 262 (40.2) 347 (53.3) 378 (58.1)
 Moderate 172 (26.4) 179 (27.5) 202 (31.0) 170 (26.1) 182 (28.0) 183 (28.1)
 High 110 (16.9) 110 (16.9) 108 (16.6) 193 (29.6) 105 (16.1) 54 (8.3)
Medication use
 Statins 560 (86.0) 564 (86.6) 563 (86.5) 602 (92.3) 587 (90.2) 464 (71.3)
 Antithrombotic drugs 633 (97.2) 640 (98.3) 641 (98.5) 637 (97.7) 631 (96.9) 637 (97.8)
 Antihypertensive drugs 581 (89.2) 580 (89.1) 590 (90.6) 586 (89.9) 576 (88.5) 572 (87.9)
Serum lipids, mmol/L§
 Total cholesterol 4.81 ± 0.95 4.73 ± 0.93 4.70 ± 0.98 4.71 ± 0.98 4.66 ± 0.88 4.83 ± 0.95
 LDL cholesterol 2.67 ± 0.81 2.60 ± 0.76 2.59 ± 0.85 2.49 ± 0.81 2.54 ± 0.75 2.80 ± 0.84
 HDL cholesterol 1.34 ± 0.36 1.30 ± 0.32 1.30 ± 0.35 1.32 ± 0.37 1.31 ± 0.35 1.29 ± 0.33
 Triacylglycerols 1.58 (1.18–2.11) 1.58 (1.18–2.21) 1.59 (1.16–2.19) 1.76 (1.28–2.48) 1.56 (1.17–2.17) 1.46 (1.11–1.97)
Plasma glucose, mmol/L§ 5.40 (4.96–5.98) 5.44 (4.96–6.10) 5.38 (4.90–6.00) 5.57 (5.04–6.28) 5.45 (5.00–6.00) 5.33 (4.90–5.84)
Prediabetes* 39 (6.1) 39 (6.1) 36 (5.6) 53 (8.2) 34 (5.3) 36 (5.6)
Family history of type 2 diabetes 104 (16.0) 104 (16.0) 104 (16.0) 108 (16.6) 101 (15.5) 108 (16.6)
Dietary factors
 Energy, kcal/day 1,750 ± 485 1,856 ± 502 1,938 ± 502 1,775 ± 501 1,858 ± 516 1,938 ± 490
 Protein, % energy 16.4 ± 3.0 15.6 ± 2.7 14.6 ± 2.5 15.8 ± 2.8 15.5 ± 3.0 15.2 ± 2.6
 Total fat, % energy 31.5 ± 5.9 32.6 ± 4.6 38.6 ± 4.9 35.0 ± 6.2 35.0 ± 5.9 36.0 ± 6.2
 SFA, % energy 12.7 ± 3.3 13.1 ± 2.8 13.5 ± 3.2 13.2 ± 3.2 12.9 ± 2.9 13.0 ± 3.0
cis-MUFA, % energy 8.4 ± 2.0 9.9 ± 1.9 11.4 ± 1.8 10.1 ± 2.4 9.9 ± 2.1 9.9 ± 2.2
 PUFA, % energy 5.6 ± 1.9 7.1 ± 0.9 10.8 ± 1.6 7.1 ± 2.2 7.6 ± 2.2 8.2 ± 2.3
 TFA, % energy 0.73 ± 0.22 0.76 ± 0.18 0.78 ± 0.16 0.76 ± 0.20 0.75 ± 0.18 0.75 ± 0.18
 Carbohydrates, % energy 52.1 ± 6.2 49.7 ± 5.6 44.6 ± 5.4 49.2 ± 6.4 49.4 ± 6.1 48.8 ± 6.4
 Fiber, g/day 21.3 ± 7.0 21.7 ± 6.7 21.1 ± 6.2 20.4 ± 6.7 21.6 ± 6.6 23.2 ± 6.9
 Cholesterol, mg/day 181 ± 68 189 ± 70 181 ± 68 187 ± 72 185 ± 66 183 ± 68
 Healthy nutrient and food score 22.1 ± 6.2 22.7 ± 6.1 22.6 ± 6.1 21.6 ± 6.3 22.6 ± 5.9 23.6 ± 5.8
Plasma FA composition
 SFA, % total FA 13.2 ± 1.2 13.1 ± 1.0 12.9 ± 1.0 14.1 ± 1.1 13.1 ± 0.7 12.1 ± 0.7
 MUFA, % total FA 22.9 ± 3.2 22.4 ± 3.1 21.6 ± 3.1 26.3 ± 3.0 22.2 ± 1.7 19.1 ± 1.8
 PUFA, % total FA 62.4 ± 4.0 63.1 ± 3.9 64.1 ± 3.7 58.0 ± 3.3 63.4 ± 1.8 67.6 ± 2.1
 n-3 PUFA, % total FA 2.4 (2.0–3.2) 2.4 (2.0–3.0) 2.3 (1.9–2.8) 2.8 (2.2–3.6) 2.4 (2.0–3.0) 2.0 (1.6–2.4)
 n-6 PUFA, % total FA 59.5 ± 4.3 60.3 ± 4.2 61.5 ± 4.1 54.7 ± 3.4 60.6 ± 1.9 65.4 ± 2.2
 Arachidonic acid (20:4n-6), % total FA 8.2 ± 2.0 8.3 ± 2.1 8.4 ± 2.1 9.4 ± 2.2 8.6 ± 1.8 6.9 ± 1.5
 Palmitic acid (16:0), % total FA 11.4 ± 0.8 11.3 ± 0.8 11.2 ± 0.8 12.1 ± 0.8 11.3 ± 0.6 10.5 ± 0.6
 Palmitoleic acid (16:1n-7), % total FA 2.9 ± 1.2 2.6 ± 1.1 2.4 ± 1.0 3.9 ± 1.4 2.5 ± 0.7 1.9 ± 0.6
 Oleic acid (18:1n-9), % total FA 18.0 ± 2.2 17.8 ± 2.2 17.3 ± 2.2 20.3 ± 2.0 17.7 ± 1.4 15.6 ± 1.5
 Liver fat proxy (16:0/18:2n-6) 0.23 ± 0.04 0.23 ± 0.04 0.22 ± 0.03 0.28 ± 0.03 0.22 ± 0.01 0.18 ± 0.01
 Estimated D6D activity (18:3n-6/18:2n-6) 0.021 ± 0.008 0.020 ± 0.008 0.020 ± 0.008 0.029 ± 0.009 0.020 ± 0.006 0.013 ± 0.004

Values are shown as mean ± SD, median (IQR), or n (%) unless otherwise indicated. % energy, percentage of total energy intake, excluding energy from alcohol.

*

Classification described in text (research design and methods).

To convert to mg/dL, divide by 0.02586 for total, LDL, and HDL cholesterol and by 0.01129 for triacylglycerols.

Fasting <4 h (n = 1,676), fasting 4 to <8 h (n = 314), fasting 8 to <12 h (n = 100), fasting ≥12 h (n = 1,035), fasting status unknown (n = 132).

§

Missing values for 61 patients for total cholesterol, HDL cholesterol, and triacylglycerols, 253 patients for LDL cholesterol, 31 patients for plasma glucose, and 1 patient for healthy nutrient and food score.